We are live on ! Find out more
HURA

TuHURA Biosciences

9 hedge funds and large institutions have $40.4K invested in TuHURA Biosciences in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

0.09% more ownership

Funds ownership: 0.12%0.2% (+0.09%)

0% more funds holding

Funds holding: 99 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

86% less capital invested

Capital invested by funds: $291K → $40.4K (-$251K)

Holders
9
Holders Change
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
3
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change

HURA Hedge Fund Activity: Q4 2023 in Review

9 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in TuHURA Biosciences (HURA) for Q4 2023, worth a combined $40.4K — down 86% from $291K a quarter earlier.

Fund positioning in HURA was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 1 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $179K. The largest seller was Morgan Stanley, exiting entirely with an estimated $13.5K sold.

  • 9 institutional investors held TuHURA Biosciences (HURA) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $40.4K of TuHURA Biosciences stock for Q4 2023, down 86% quarter-over-quarter.
  • 2 funds opened new TuHURA Biosciences positions in Q4 2023 and 2 closed out, a net change of 0 holders.
  • The largest TuHURA Biosciences buyer in Q4 2023 was Acadian Asset Management, an estimated $179K added.
  • The largest TuHURA Biosciences seller in Q4 2023 was Morgan Stanley, an estimated $13.5K sold.

Based on aggregated 13F filings for Q4 2023.